Cases of Patients with OUD. Objectives

Size: px
Start display at page:

Download "Cases of Patients with OUD. Objectives"

Transcription

1 Cases of Patients with OUD Soraya Azari, MD Objectives To dive further into cases of patients related to OUD, including some more challenging cases from the inpatient setting. To refine your skills at counseling patients about options for management of their OUD. To consider additional resources to aid with management in your respective health systems. 1

2 Case 1 A 32yo F with a history of low back pain, obesity, prior motor vehicle accident with hardware in, and recurrent UTIs that is admitted with urosepsis. She states that she is prescribed Percocet by her primary doctor for control of her chronic pain. VS and exam are notable for T38.2, HR 106, normal BP, and O2 sat. She is diaphoretic, anxious appearing, and has CVA tenderness. Question What additional information do you want to know on history & physical? What tests do you want to order? 2

3 Additional Info History She states that she is getting hassled more to get her medication. She s had to visit several doctors to get her usual meds. She has needed more pills recently to keep up w/her pain. She reports the car accident was 5 years ago and she was basically run over and now has hardware in her ankle. Her medications were started them and she s needed them since then to manage her ankle pain. The meds allow her to function. She is currently staying with her mom and has a five year old child, who is in daycare. She is currently not working and hopes to apply for SSI for her ankle pain. She denies use of drugs (except marijuana, which she uses for pain), no alcohol use ( I drank before my accident and I would never go back to that ), and no tobacco use. History Additional Info You check a prescription activity report that shows 5 different providers in the past 3 months You are not able to access records from her primary doctor s office. Physical Pupils are 5mm and reactive; +rhinorrhea; +diaphoresis; +anxious appearing and with arms stretched out she has a visible tremor 3

4 Additional Info You check a prescription activity report and see the following: 4 different prescribers, with all prescriptions for a quantity of 5 10 days Labs Urine drug screen: positive opiates and oxycodone 4

5 Question What do you want to do with this patient (besides fluids, antibiotics, VS monitoring, etc)? Wesson, D. R., & Ling, W J Psychoactive Drugs, 35(2), Available online as pdf 5

6 From: Interpretation of Urine Drug Testing in Pain Patients Pain Med. 2012;13(7): doi: /j x Pain Med Wiley Periodicals, Inc. Does this patient have an opioid use disorder? 4Rs Risk of bodily harm Relationship trouble Role Failure Repeated attempts to cut back 4Cs Loss of Control Consequences** Compulsion Craving Tolerance** Withdrawal 6

7 DSM-5 Criteria for Substance Use Disorders Recommendations and Rationale Risk bodily harm Relationship trouble Role Failure Compulsion Compulsion Loss of Control Repeated try cut back Consequences Craving a One or more abuse criteria within a 12-month period and no dependence diagnosis; applicable to all substances except nicotine, for which DSM-IV abuse criteria were not given. b Three or more dependence criteria within a 12-month period. c Two or more substance use disorder criteria within a 12-month period. d Withdrawal not included for cannabis, inhalant, and hallucinogen disorders in DSM-IV. Cannabis withdrawal added in DSM-5. Source: Am J Psychiatry. 2013;170(8): Case Continued What will be your next steps? Role play for 5 minutes Patient Provider Goal of the conversation: Communicate your concern for an opioid use disorder Describe treatment options while she s in the hospital Explain the plan moving forward 7

8 Remember You do NOT need an x license or waiver to give buprenorphine or methadone to a hospitalized patient with OUD and withdrawal 8

9 Case Continued The patient receives a dose of buprenorphine and feels much better She completes treatment of her pyelonephritis and is referred to outpatient buprenorphinenaloxone waivered providers (if she desires). She is offered prescription of naloxone for overdose prevention. She is not discharged with opioid analgesics for pain. 9

10 Case 2 KB is a 57yo M with a hx of poorly controlled DM, CAD, cocaine use disorder, HTN, depression, severe LE neuropathy now primarily using a power wheelchair, opioid use disorder on methadone maintenance p/w non healing foot ulcer that probes to bone and elevated ESR c/w osteomyelitis. He is admitted for IV antibiotics and surgical consultation. He is on methadone 30mg daily in a methadone maintenance program. He was previously on 60mg, but had his dose reduced because of sedation. Case 2 Meds include: Glargine insulin 12 units q bedtime Atorvastatin 80mg daily Metformin 500mg bid Zinc 220mg daily Melatonin 3mg q bedtime Venlafaxine XR 150mg daily Pregabilin 150mg BID Aspirin 81mg daily Docusate 100mg BID Ondansetron 4mg 10

11 Case continued You get an ECG and he has a QTc of 600msec. Question What do you want to do to manage this patient? Who do you want to talk to? Talk as a group x5 10 minutes & then report back 11

12 Case continued The astute hospitalist contacted the medical providers at his methadone clinic. They were able to explain: He has old ECGs on 60mg daily with a QTc of 460msec He has had ongoing use of cocaine and opioids, especially since his dose has been reduced. His providers at methadone clinic wanted him to come back at peak [methadone dose] to assess for sedation so they could increase his dose, but he was never able to do that. Nevertheless, he has been dosing most days. Methadone Clinic Pearls Goals of treatment Cessation or reduction of opioid use in order to minimize harm Functional improvement resumption of work, reunification with family Right Dose? Dose that allows the person to meet these goals Impossible to say exactly, but at/above 80mg is considered important to decrease craving Consistent attendance is important to establish a therapeutic level of the medication 12

13 Approach to Sedation Perspective of a methadone clinic Methadone effect? Drug interaction Illicit or licit substance use: prescribed opioids, illicit opioids, BZDs, cocaine, speed, atypical antipsychotics (esp olanzapine), anti cholinergics Secondary medical disease: pulmonary disease, thyroid disease, metabolic disease (i.e., DM), CNS process, liver disease (i.e., HE) etc. Psychiatric disease Interventions Dose reduction Observe patients at peak methadone dosing (2 4 hrs after dose) Urine drug screen Medical evaluation QTc Prolongation and Methadone QTc prolongation >450msec (men) and >470msec (women) QTc >500 is clinically significant risk for developing arrhythmia and torsades de pointes In case series of TdP and high dose methadone, 16/17 patients had other risk factors for TdP MOA: possible blockage of potassium channels, leading to prolonged repolarisation and QTc prolongation Variable recommendations for patients maintained in methadone programs Universal screening v. Screening at >150mg/day UK Pharmacovigilance Expert Advisory Group (MHRA criteria) recommended: ECG monitoring if on high dose (>100mg), and/or other reasons to have QT prolongation such as heart orliver disease, electrolyte abnormalities, taking CYP 3A4 inhibitors, or other drugs that can prolong the QTc Study: 57% would need screening ecg (75% if include cocaine as QTc prolonging drug) 18% had prolonged QTc (none above 500), no TdP. Daily dose and use of stimulants associated with prolonged QTc Protocols within clinic (ours) Screening starts at 100mg daily, unless patient has a history of cardiac disease, prolonged QTc, or other risk factors Repeat ECGs after every 20 40mg increase above 100mg Elevated QTc: risk benefit assessment How are they doing in treatment? [remember their OUD is a fatal disease!!!] Do they have reversible causes of the QTc prolongation? Is there a new culprit medicine? Check for drug interactions and other meds that prolong the QTc. Mayet S, et al. Drug and Alcohol Review. 2011;30(4):

14 Case Continued The hospitalist stopped all medications that were QTc prolonging, corrected electrolyte abnormalities, and checked daily ECGs for the QTc interval. Repeat ECGs still showed a QTc of 500msec. Question What do you want to do with the patient s methadone? Do you want to switch him to buprenorphine? 14

15 Methadone to Buprenorphine Reasons to switch Buprenorphine is less sedating because of the ceiling effect Buprenorphine might better address his chronic pain Buprenorphine allows irregular dosing Methadone does not seem safe Disposition options? Reasons to not switch Patient engaged with methadone treatment (10+ year hx in the clinic), including working w/case management Patient preference Epilogue Patient had serial EKG monitoring and his QTc decreased back to 460msec. He continued on 30mg daily of methadone. He was taken off telemetry. He continued to receive IV antibiotics in the hospital, but about 5d after normalization of his QTc, he had an arrest and died. This 58 year old man with type 2 diabetes mellitus, viral hepatitis C cirrhosis, hypertension and moderate to severe atherosclerotic cardiovascular disease developed chronic ischemic heart disease superimposed on hypertensive heart disease lead to a lethal arrhythmia and sudden cardiac death. 15

16 Case 3 DS is a 58yo M with a hx of Afib, CHF, prior orthopedic injuries, OUD, and obesity coming in with new patellar fracture after a fall. He is on bupe nal 8mg PO TID Group Discussion How will you manage his acute pain complaints? 16

17 Summary Consider yourself a front line provider for diagnosis of an opioid use disorder in the hospital. You CAN and SHOULD administer methadone or buprenorphine to anyone with an opioid use disorder during their acute hospitalization. Utilize the Project SHOUT resources if this is unfamiliar to your hospital system. Summary Continued Methadone to bupe transitions are complicated seek addiction or pain med consultation for assistance. Remember the drug interactions and QTc prolongation of methadone. For acute pain treatment for patients maintained on bupe or methadone, use full agonist opioids as needed (but remember multi modal treatment) and coordinate w/the patient s outpatient provider if rx ing upon d/c (or taper off while in the hospital) 17

Multiple Choice Questions

Multiple Choice Questions Multiple Choice Questions 25yo M presents without psychiatric or medical history, with complaint of tremor to the ER. He denies drinking alcohol but his friend at bedside takes you to the side and reports

More information

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over

More information

Agenda. Case Discussions. Managing Acute & Chronic Pain (requiring opioid analgesics) in Patients on MAT. Daniel Alford, MD Disclosures

Agenda. Case Discussions. Managing Acute & Chronic Pain (requiring opioid analgesics) in Patients on MAT. Daniel Alford, MD Disclosures Managing Acute & Chronic Pain (requiring opioid analgesics) in Patients on MAT Case Discussions August 26, 2014 PCSS MAT Webinar Sponsored by the American Psychiatric Association Daniel P. Alford, MD,

More information

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St.

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners, Albany, NY Assistant Professor of Medicine,

More information

Medication Assisted Treatment. Nicole Gastala, MD

Medication Assisted Treatment. Nicole Gastala, MD Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants

More information

Methadone Maintenance 101

Methadone Maintenance 101 Methadone Maintenance 101 OTP/DAILY DOSING CLINICS - ANDREW PUTNEY MD Conflicts of Interest - Employed by Acadia HealthCare 1 Why Methadone? At adequate doses methadone decreases opioid withdrawal symptoms

More information

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 NORTHWEST AIDS EDUCATION AND TRAINING CENTER Opioid Use Disorders Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 Opioid Use Disorders Importance of opioid use disorders Screening and

More information

WHAT SHOULD WE DO ABOUT BENZODIAZEPINES? Miriam Komaromy, MD Associate Director, Project ECHO August 2014

WHAT SHOULD WE DO ABOUT BENZODIAZEPINES? Miriam Komaromy, MD Associate Director, Project ECHO August 2014 WHAT SHOULD WE DO ABOUT BENZODIAZEPINES? Miriam Komaromy, MD Associate Director, Project ECHO August 2014 EPIDEMIOLOGY OF BENZO USE 7-18% of US population uses a benzo for medical purposes each year Average

More information

6/27/2017. Disclosures. Overview. Case Overview

6/27/2017. Disclosures. Overview. Case Overview Disclosures Jessica Gray, MD Nothing to disclose Daniel Alford, MD, MPH Nothing to disclose John Renner, MD Overview The intersection of active illicit opioid use, acute pain and severe mental illness

More information

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE Valerie Carrejo, MD Assistant Professor UNM Family Medicine Advances in Primary Care April 14, 2017 Objectives Review the basic

More information

Opioid Use in Youth. Amy Yule M.D. March 2,

Opioid Use in Youth. Amy Yule M.D. March 2, Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin

More information

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Medication-Assisted Treatment. What Is It and Why Do We Use It? Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite

More information

1) To understand the scope of the opioid epidemic with relation to Emergency Departments 2) To gain insight into some emerging Emergency Medicine

1) To understand the scope of the opioid epidemic with relation to Emergency Departments 2) To gain insight into some emerging Emergency Medicine 1) To understand the scope of the opioid epidemic with relation to Emergency Departments 2) To gain insight into some emerging Emergency Medicine solutions to the Opioid Epidemic 3) To learn about the

More information

BEFORE THE NORTH CAROLINA MEDICAL BOARD ) ) ) ) ) The North Carolina Medical Board ( Board ) has preferred

BEFORE THE NORTH CAROLINA MEDICAL BOARD ) ) ) ) ) The North Carolina Medical Board ( Board ) has preferred BEFORE THE NORTH CAROLINA MEDICAL BOARD In Re: James Stewart Campbell, M.D., Respondent. ) ) ) ) ) AMENDED NOTICE OF CHARGES AND ALLEGATIONS; NOTICE OF HEARING The North Carolina Medical Board ( Board

More information

Opioid Dependence and Buprenorphine Management

Opioid Dependence and Buprenorphine Management Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale

More information

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)

More information

Patient Initiation: Buprenorphine/Naloxone

Patient Initiation: Buprenorphine/Naloxone Patient Initiation: Buprenorphine/Naloxone Kristin Wason, MSN, APRN, CARN Office-Based Addiction Treatment Program Boston Medical Center *Images used for educational purposes only. All copyrights belong

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL

OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL Brian Fuehrlein, MD PhD VA Connecticut Healthcare System and Yale University I have no conflicts of interest or relevant financial

More information

1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW)

1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW) Dr. Paul A. Farnan farnan@mail.ubc.ca HealthQuest Occupational Health Corporation Alliance Medical Monitoring I have no financial interests or affiliation with any pharmaceutical industry or manufacturer

More information

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States

More information

POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE

POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE MARK DUNCAN, MD November 8, 2018 SPEAKER

More information

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008 Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality

More information

Substance Use Disorders

Substance Use Disorders Substance Use Disorders Substance Use Disorder This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and

More information

Prepublication Requirements

Prepublication Requirements Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals

More information

Expanding Access To Medication Assisted Treatment for Opioid Use Disorders to Patients in the Hospital

Expanding Access To Medication Assisted Treatment for Opioid Use Disorders to Patients in the Hospital Expanding Access To Medication Assisted Treatment for Opioid Use Disorders to Patients in the Hospital August 28, 2018 Hosted by John A. Renner, Jr., MD, DLFAPA Professor of Psychiatry Boston University

More information

Management of Opioid Use Disorder in Primary Care

Management of Opioid Use Disorder in Primary Care 1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,

More information

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South

More information

2/7/2017. Avoid compassion traps. Avoid All or Nothing Traps. Some Explanatory Models of Addiction

2/7/2017. Avoid compassion traps. Avoid All or Nothing Traps. Some Explanatory Models of Addiction Avoid compassion traps Do you want me to lose my job, do you want me to be on the street? I want you to have safe and effective pain control and it is my medical opinion that your current medicine won

More information

Polysubstance Use & Medication-Assisted Treatment

Polysubstance Use & Medication-Assisted Treatment Polysubstance Use & Medication-Assisted Treatment DSM-V eliminated polysubstance disorder, instead specifying each drug of abuse and dependence. Substance-use disorder is a combination of the two DSM-IV

More information

Managing Pain in the Patient with Opioid Use Disorder: Inpatient Management. Melissa Weimer, DO, MCR Oregon Health & Science University

Managing Pain in the Patient with Opioid Use Disorder: Inpatient Management. Melissa Weimer, DO, MCR Oregon Health & Science University Managing Pain in the Patient with Opioid Use Disorder: Inpatient Management Melissa Weimer, DO, MCR Oregon Health & Science University 1 Educational Objectives At the conclusion of this activity participants

More information

EMEA PUBLIC STATEMENT ON THE RECOMMENDATION TO SUSPEND THE MARKETING AUTHORISATION FOR ORLAAM (LEVACETYLMETHADOL) IN THE EUROPEAN UNION

EMEA PUBLIC STATEMENT ON THE RECOMMENDATION TO SUSPEND THE MARKETING AUTHORISATION FOR ORLAAM (LEVACETYLMETHADOL) IN THE EUROPEAN UNION The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 19 April 2001 EMEA/8776/01 EMEA PUBLIC STATEMENT ON THE RECOMMENDATION TO SUSPEND THE MARKETING

More information

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January

More information

The Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM

The Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM The Prescription Review Program and College Expectations Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM April 28, 2017 Disclosure Relationship with commercial interests: None Professional roles: Addictions

More information

Medication Assisted Treatment

Medication Assisted Treatment Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,

More information

On the Frontlines of the Opioid Epidemic: Barriers and Challenges in the Emergency Department

On the Frontlines of the Opioid Epidemic: Barriers and Challenges in the Emergency Department On the Frontlines of the Opioid Epidemic: Barriers and Challenges in the Emergency Department Priya E. Mammen, MD, MPH Director of Public Health Programs Department of Emergency Medicine Sidney Kimmel

More information

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication

More information

Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM. Disclosures

Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM. Disclosures Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM Disclosures Dr. Bhatnagar: no disclosures to report Dr. Ewing: no disclosures to report 1 Our

More information

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine

More information

Prescription Opioid Addiction

Prescription Opioid Addiction CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett

More information

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings BRIAN GARVEY, MD, MPH REBECCA CANTONE, MD OREGON HEALTH & SCIENCE UNIVERSITY SCAPPOOSE RURAL HEALTH CENTER Disclosures

More information

The Challenging Patient with Chronic Opioid Usage MD ACP Meeting

The Challenging Patient with Chronic Opioid Usage MD ACP Meeting The Challenging Patient with Chronic Opioid Usage. 2018 MD ACP Meeting Darius A. Rastegar, MD March 12, 2018 1 Prescribing Opioids: A question of balance Opioids are an effective treatment for acute pain.

More information

Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline

Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline: To help providers make informed decisions about acute and chronic pain treatment -pain lasting longer than three months

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose

More information

Medication Assisted Treatment: Setting Up, Operating, Integrating into Primary Care. Ako Jacintho, MD Director of Addiction Medicine HealthRIGHT 360

Medication Assisted Treatment: Setting Up, Operating, Integrating into Primary Care. Ako Jacintho, MD Director of Addiction Medicine HealthRIGHT 360 Medication Assisted Treatment: Setting Up, Operating, Integrating into Primary Care Ako Jacintho, MD Director of Addiction Medicine HealthRIGHT 360 How do you set up your practice? Staff Needed - Provider

More information

Management of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013

Management of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial

More information

Clinical Policy: Lofexidine (Lucemyra) Reference Number: ERX.NPA.88 Effective Date:

Clinical Policy: Lofexidine (Lucemyra) Reference Number: ERX.NPA.88 Effective Date: Clinical Policy: (Lucemyra) Reference Number: ERX.NPA.88 Effective Date: 07.31.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy Medication Assisted Treatment for Substance Abuse in Primary Care Dan Vinson August 1, 2013 1 The Big change in addiction medicine? These diseases are rapidly becoming medical diseases. Done are the days

More information

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Disclosures S C O T T S T E I G E R, M D, F A C P, D A B A M A S S I S T A N T C L I N I C A L P R O F E S S O R D I V I S I O N O F G

More information

Cannabis and Opioids in AANHPI David Kan, MD, DFASAM University of California, San Francisco

Cannabis and Opioids in AANHPI David Kan, MD, DFASAM University of California, San Francisco Substance Use in AANHPI Cannabis and Opioids in AANHPI David Kan, MD, DFASAM University of California, San Francisco In general: Lower rates of illegal drug use Binge Alcohol use Substance Use Disorder

More information

John Murphy DO, MS Lynx Healthcare

John Murphy DO, MS Lynx Healthcare Addiction to Pain Medication and Treatment John Murphy DO, MS Lynx Healthcare No Disclosures Objectives 1 Understand basic neurobiology and learning theory around opioid addiction 2 Identify aberrant behavior

More information

National Opioid Treatment Guideline Dr. Ronald Lim

National Opioid Treatment Guideline Dr. Ronald Lim National Opioid Treatment Guideline Dr. Ronald Lim (MD, CCFP, DFASAM, ABAM(D), FISAM, CCSAM, MRO) Clinical Assistant Professor, Department of Psychiatry and Family Practice Cumming School of Medicine University

More information

The Unseen Consequences of Prescription Drug Abuse. Stephen Loyd, M.D.

The Unseen Consequences of Prescription Drug Abuse. Stephen Loyd, M.D. The Unseen Consequences of Prescription Drug Abuse Stephen Loyd, M.D. Stephen Loyd, M.D. Receives no commercial support, in any form, from pharmaceutical companies or anyone else Medical Director for Substance

More information

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D. Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals

More information

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?

More information

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives

More information

Opioid Use Disorder Treatment Initiation in Diverse Settings

Opioid Use Disorder Treatment Initiation in Diverse Settings Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5

More information

Addiction Medicine: What s new for primary care

Addiction Medicine: What s new for primary care Addiction Medicine: What s new for primary care Dan Vinson, MD Family and Community Medicine How to talk so our patients listen, and listen so our patients talk. 1 2 Comfortably engaging your patient in

More information

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin

More information

6/2/16. Soraya Azari MD Scott Steiger MD. Dr. Soraya Azari Nothing to disclose Dr. Scott Steiger Nothing to disclose

6/2/16. Soraya Azari MD Scott Steiger MD. Dr. Soraya Azari Nothing to disclose Dr. Scott Steiger Nothing to disclose Soraya Azari MD Scott Steiger MD Dr. Soraya Azari Nothing to disclose Dr. Scott Steiger Nothing to disclose 1 In surveys of waivered buprenorphine prescribers, a significant percentage do NOT prescribe

More information

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA Professor of Psychiatry,

More information

Opioids for Pain Treatment in Persons with Opioid Use Disorder. Patricia Pade, MD Seddon R. Savage, MD, MS Melissa Weimer, DO, MCR

Opioids for Pain Treatment in Persons with Opioid Use Disorder. Patricia Pade, MD Seddon R. Savage, MD, MS Melissa Weimer, DO, MCR Opioids for Pain Treatment in Persons with Opioid Use Disorder Patricia Pade, MD Seddon R. Savage, MD, MS Melissa Weimer, DO, MCR 1 Educational Objectives At the conclusion of this activity participants

More information

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners Grand Rounds October 11, 2017 Disclosures One

More information

Disclosures. The Problem. The Problem. The Problem. The Problem. Buprenorphine Use in Combined Chronic Pain and Opioid Addiction

Disclosures. The Problem. The Problem. The Problem. The Problem. Buprenorphine Use in Combined Chronic Pain and Opioid Addiction Buprenorphine Use in Combined Chronic Pain and Opioid Addiction Sandra D. Comer, Ph.D. Disclosures Within the last 3 years, consulted for AstraZeneca, BioDelivery Sciences, Camarus, Clinilabs, Grunenthal,

More information

Adolescent Substance Abuse

Adolescent Substance Abuse Adolescent Substance Abuse WHY IT S A PROBLEM AND WHAT WE NEED TO KNOW AS ANESTHESIA PROVIDERS BRIDGET L. MULDOWNEY MD ASSISTANT PROFESSOR OF ANESTHESIOLOGY UNIVERSITY OF WISCONSIN- SCHOOL OF MEDICINE

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance

More information

9/17/2018 MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSION JOIN JUSTICE LEAGUE I M POSSIBLE HEPBURN

9/17/2018 MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSION JOIN JUSTICE LEAGUE I M POSSIBLE HEPBURN MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSION JOIN JUSTICE LEAGUE I M POSSIBLE HEPBURN 1 ADDICTION PREVENTION & TREATMENT SAVES LIVES According to the Food and Drug Administration s standards for

More information

Chronic Pain Pharmacist role in the clinic

Chronic Pain Pharmacist role in the clinic Chronic Pain Pharmacist role in the clinic WSPA Annual Meeting 2015 Alvin Goo, PharmD Clinical Associate Professor University of Washington Schools of Pharmacy and Family Medicine Speakers Declaration

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM OAT Transitions - focus on microdosing Mark McLean MD MSc FRCPC CISAM DABAM Disclosures No pharmaceutical industry or other financial conflicts of interest Study Physician for research funded by Canadian

More information

The Importance of Psychological Treatment and Behavioral Support

The Importance of Psychological Treatment and Behavioral Support The Importance of Psychological Treatment and Behavioral Support Michael W. Otto, PhD Department of Psychological and Brain Science Boston University Conflicts and Acknowledgements No industry funding

More information

Psychosocial Treatments for Opioid Use Disorder Overview

Psychosocial Treatments for Opioid Use Disorder Overview Psychosocial Treatments for Opioid Use Disorder Overview Nalan Ward, MD Director Outpatient Addiction Services Department of Psychiatry Massachusetts General Hospital *Images used for educational purposes

More information

THE UNSTABLE BUPRENORPHINE- NALOXONE PATIENT

THE UNSTABLE BUPRENORPHINE- NALOXONE PATIENT Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences THE UNSTABLE BUPRENORPHINE- NALOXONE PATIENT MARK DUNCAN MD UNIVERSITY OF WASHINGTON SPEAKER DISCLOSURES Any conflicts

More information

Treatment Alternatives for Substance Use Disorders

Treatment Alternatives for Substance Use Disorders Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict

More information

Buprenorphine as a Treatment Option for Opioid Use Disorder

Buprenorphine as a Treatment Option for Opioid Use Disorder Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital

More information

PATIENT INTAKE: MEDICAL HISTORY. Name. Address. Phone (W) (H) (C) DOB Age SS# Emergency Contact. Relationship to patient Phone

PATIENT INTAKE: MEDICAL HISTORY. Name. Address. Phone (W) (H) (C) DOB Age SS# Emergency Contact. Relationship to patient Phone PATIENT INTAKE: MEDICAL HISTORY Name Address Phone (W) (H) (C) DOB Age SS# Emergency Contact Relationship to patient Phone Primary care physician Phone Have you ever had an EKG? Y N Date Current or past

More information

Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder

Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare

More information

BASIC VOLUME. Elements of Drug Dependence Treatment

BASIC VOLUME. Elements of Drug Dependence Treatment BASIC VOLUME Elements of Drug Dependence Treatment Module 3 Principles of CBT and relapse prevention strategies Introduction to Cognitive Behavioural Therapy Basics of pharmacological treatment Workshop

More information

Update on Pain: Collaborative Care for the Complex Patient

Update on Pain: Collaborative Care for the Complex Patient Update on Pain: Collaborative Care for the Complex Patient Nirmala R. Abraham, MD Medical Director Sycamore Pain Management Center Kettering Health Network Objectives Standardized approach to patient care

More information

*IN10 BIOPSYCHOSOCIAL ASSESSMENT*

*IN10 BIOPSYCHOSOCIAL ASSESSMENT* BIOPSYCHOSOCIAL ASSESSMENT 224-008B page 1 of 5 / 06-14 Please complete this questionnaire and give it to your counselor on your first visit. This information will help your clinician gain an understanding

More information

OBSERVATION SHEET TOPIC CLINICAL SCENARIO. OBSERVATIONS MADE (Use the skills objectives/ provider tasks to evaluate the conversation)

OBSERVATION SHEET TOPIC CLINICAL SCENARIO. OBSERVATIONS MADE (Use the skills objectives/ provider tasks to evaluate the conversation) OBSERVATION SHEET TOPIC CLINICAL SCENARIO OBSERVATIONS MADE (Use the skills objectives/ provider tasks to evaluate the conversation) FEEDBACK: WHAT WENT WELL FEEDBACK: THINGS TO CONSIDER DEBRIEF: Observer

More information

OBSERVATION SHEET TOPIC CLINICAL SCENARIO. OBSERVATIONS MADE (Use the skills objectives/ provider tasks to evaluate the conversation)

OBSERVATION SHEET TOPIC CLINICAL SCENARIO. OBSERVATIONS MADE (Use the skills objectives/ provider tasks to evaluate the conversation) OBSERVATION SHEET TOPIC CLINICAL SCENARIO OBSERVATIONS MADE (Use the skills objectives/ provider tasks to evaluate the conversation) FEEDBACK: WHAT WENT WELL FEEDBACK: THINGS TO CONSIDER DEBRIEF: Observer

More information

MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER

MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER JOHN E LOPES Jr., DHSC, PA-C Associate Professor, Physician Assistant Program Central Michigan University and Project Director Medication-assisted

More information

If so, when: Demographic Information Male Transgender Height: Weight: Massachusetts Resident? Primary Language: Are you currently homeless?

If so, when: Demographic Information Male Transgender Height: Weight: Massachusetts Resident? Primary Language: Are you currently homeless? Application Form rev. 9/09 Jeremiah's Inn P.O. Box 30035 1059 Main St., Worcester, MA 01603-0035 FAX 508.793.9568 Phone 508.755.6403 Last Name: Suffix: First Name: Middle Initial: Alias: Referral Information

More information

Poisoning Deaths vs. Motor Vehicle Related Injury Deaths, MA Residents ( )

Poisoning Deaths vs. Motor Vehicle Related Injury Deaths, MA Residents ( ) Source: National Vital Statistics Poisoning Deaths vs. Motor Vehicle Related Injury Deaths, MA Residents (1997 2008) The source of the data is: Registry of Vital Records and Statistics, MA Department of

More information

Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17

Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient

More information

Cardiac Risk Assessment in the Preoperative period

Cardiac Risk Assessment in the Preoperative period Cardiac Risk Assessment in the Preoperative period Catherine Curley, MD May, 2017 Disclosures I am not a cardiologist! 1 Case 1 78 yo man presenting to the ED after mechanical fall on his driveway. Found

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education

More information

GOALS AND OBJECTIVES

GOALS AND OBJECTIVES SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES

More information

Delirium. Dr. Lesley Wiesenfeld. Deputy Psychiatrist in Chief, Mount Sinai Hospital. Dr. Carole Cohen

Delirium. Dr. Lesley Wiesenfeld. Deputy Psychiatrist in Chief, Mount Sinai Hospital. Dr. Carole Cohen Delirium Dr. Lesley Wiesenfeld Deputy Psychiatrist in Chief, Mount Sinai Hospital Dr. Carole Cohen Department of Psychiatry, University of Toronto and Sunnybrook Health Sciences Centre Case Study Mrs B

More information

Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers

Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers Marwan S. Haddad, M.D. Community Health Center, Inc. Connecticut September 16, 2008 Community Health Center, Inc.

More information

Module 6: Overview Opioid Dependence Treatment with Buprenorphine/Naloxone

Module 6: Overview Opioid Dependence Treatment with Buprenorphine/Naloxone Module 6: Overview Opioid Dependence Treatment with Buprenorphine/Naloxone History of Medical Practice for Opioid Addiction in the U.S. Physicians had been liberal prescribers of morphine in late 1800s/early

More information

Addiction History. Patient Assessment. Objectives. Cost. Initial Screen. Patient Assessment 25/04/2017. Substances. Age Started

Addiction History. Patient Assessment. Objectives. Cost. Initial Screen. Patient Assessment 25/04/2017. Substances. Age Started Addiction History Patient Assessment Methadone and Suboxone 2017 Dr. Morris Markentin, 2017 Substances Current substance use and amount Age Started Each substance Route of use each substance Inhalation

More information

Basics of Benzodiazepine Use Disorder. DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR

Basics of Benzodiazepine Use Disorder. DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR Basics of Benzodiazepine Use Disorder DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR Disclosures Speaker: Melissa Weimer, DO, MCR, has nothing to disclose. Planning Committee: The members

More information

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA THE OPIOID CRISIS DEFINING THE CRISIS KATHLEEN DUPPER, MD MEDICAL DIRECTOR, HUNTSVILLE RECOVERY 19 th Annual Perinatal Conference: The Opioid Crisis September 21, 2018 DEFINING THE CRISIS NUMBER OF OPIOID-RELATED

More information